BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ondek Limited Announced the Appointment of Dr Jenny Harry as CEO


3/18/2013 9:12:29 AM

March 18, 2013 -- Australian drug delivery system company Ondek Limited today announced the appointment of Dr Jenny Harry as Chief Executive Officer.

Ondek is developing innovative ways to deliver medical therapies using the groundbreaking discoveries of Australian Nobel Laureate Barry Marshall. The Company is currently working to use the stomach bacteria that helped win Dr Marshall the top prize in medicine to fight childhood asthma and allergies.

Ondek Chairman Peter Hammond said, “Dr Harry will play a key role in the global commercialisation of Ondek’s novel drug delivery technology. She has already had a significant and positive impact on the business and her experience and skills will be invaluable as we progress through the clinic and negotiate commercial alliances.”

Dr Harry is an experienced CEO of global biotechnology businesses. Before joining Ondek she served as CEO and Managing Director of Tyrian Diagnostics Limited (ASX: TDX) where she led the transformation of the Company from research and development to diagnostics and oversaw commercialisation of its first diagnostic products. She has experience in leading high performing teams, strategic planning and portfolio development, structuring and negotiating agreements with multi-nationals, raising capital for early stage biotechnology companies and investor relations. Dr Harry has a PhD in developmental biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Dr Harry is based in Sydney at the offices of Exto Partners Pty Ltd.

For more information contact:

Dr Jenny Harry

CEO Ondek Limited

02 9332 0600

Tim Allerton or Andrew Geddes

City PR

02 9267 4511

About Ondek

Ondek Pty Ltd is an Australian biotechnology company developing a novel drug delivery platform, known as the “Helicobacter pylori Platform Technology” (HPPT).

The platform utilises the unique characteristics of a genetically modified Helicobacter pylori bacterium to deliver a diverse range of therapeutics to the patient, including immune therapies, biopharmaceuticals, other drugs and vaccines.

Ondek was founded by Professor Barry Marshall, a world authority and co-discoverer of the Helicobacter pylori organism and co-recipient of the 2005 Nobel Prize for Medicine and Physiology.

www.ondek.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES